About: Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
Creator	Krakowka, Steven Beseme, Sarah Dahlberg, Albert Fitzgerald, Kara Mamber, Stephen Osborn, Jeffrey Pond-Tor, Sunthorn Rhodes, Ryan Saberski, Lloyd Wright, Neal Mcmichael, John
Source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms and severity. This report briefly describes the following four unconventional but commercially accessible immunomodulatory agents that can be employed in clinical trials to evaluate their effectiveness at alleviating disease symptoms and severity: low-dose oral interferon alpha, microdose DNA, low-dose thimerosal, and phytocannabinoids.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1128/msphere.00288-20
bibo:pmid	32404512
has license	cc-by
sha1sum (hex)	73b1bed15ca72b533d3e362622e0d92797101eb7
schema:url	https://doi.org/10.1128/msphere.00288-20
resource representing a document's title	Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
has PubMed Central identifier	PMC7227768
has PubMed identifier	32404512
schema:publication	mSphere
resource representing a document's body	covid:73b1bed15ca72b533d3e362622e0d92797101eb7#body_text
is schema:about of	named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'protein' named entity 'cytokines' named entity 'antiviral agents' named entity 'phytocannabinoids' named entity 'immunomodulatory' named entity 'TO INHIBIT' named entity 'CAUSE' named entity 'EFFECTIVE' named entity 'FOLLOWING' named entity 'CHEMOKINES' named entity 'REPORT' named entity 'ORAL' named entity 'CORONAVIRUSES' named entity 'CYTOKINES' named entity 'VARIETY' named entity 'THIMEROSAL' named entity 'CORONAVIRUS' named entity 'IMMUNOMODULATORY ACTIVITY' named entity 'INTERLEUKIN-1 ' named entity 'protein' named entity 'vaccine' named entity 'Th2' named entity 'clinical trials' named entity 'disease' named entity 'Th2' named entity 'interferon alpha' named entity 'thimerosal' named entity 'immunomodulatory' named entity 'SARS coronavirus 2' named entity 'protein' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'low-dose' named entity 'low-dose' named entity 'COVID-19' named entity 'clinical trials' named entity 'IL-6' named entity 'chronic bronchitis' named entity 'cellular immune responses' named entity 'TNFSF13B' named entity 'viscosity' named entity 'IL10RB' named entity 'thimerosal' named entity 'morbidity' named entity 'IL-4' named entity 'Caribbean' named entity 'immunomodulatory' named entity 'microdose' named entity 'phytocannabinoids' named entity 'clinical trial' named entity 'Kyoto Encyclopedia of Genes and Genomes' named entity 'gene' named entity 'coronaviruses' named entity 'MERS' named entity 'Pulmozyme' named entity 'vaccines' named entity 'vaccines' named entity 'cytokine' named entity 'fever' named entity 'evidence-based' named entity 'clinical trial' named entity 'health care' named entity 'antiviral' named entity 'dental trauma' named entity 'gene' named entity 'thimerosal' named entity 'active pharmaceutical ingredient' named entity 'respiratory ailments' named entity 'microdose' named entity 'clinical trial' named entity 'thimerosal'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software